Clinical trial
A Study to Evaluate the Hematologic Response Rate (the Rate at Which the…
NCT00341055 · Johnson & Johnson Pharmaceutical Research & Development, L.L.C., Industry · Completed
Key facts
| NCT number | NCT00341055 |
|---|---|
| Title | A Study to Evaluate the Hematologic Response Rate (the Rate at Which the Hemoglobin Level Rises) of PROCRIT (Epoetin Alfa) Given at a Dose of 80,000 Units Once Weekly to Cancer Patients With Anemia Who Are Receiving Chemotherapy. |
| Official title | A Pilot Study to Evaluate the Hematologic Response Rate of PROCRIT (Epoetin Alfa) at 80,000 Units Once Weekly in Anemic Cancer Patients Receiving Chemotherapy |
| Lead sponsor | Johnson & Johnson Pharmaceutical Research & Development, L.L.C., Industry |
| Collaborators | Ortho Biotech Products, L.P. Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Anemia, Cancer, Chemotherapy |
| Intervention type | Drug |
| Interventions | Epoetin alfa |
| Enrollment | 69 |
| Start date | Jun 1, 2003 |
| Completion | May 1, 2004 |
| First posted | Jun 21, 2006 |
| Last update posted | Jun 10, 2011 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: